In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus.

In a recent antitrust arbitration ruling, Prime Therapeutics, a pharmacy benefit manager (PBM) owned by 19 Blue Cross and ...

The Federal Trade Commission’s rule targeting bait-and-switch tactics by car dealers was vacated Monday by a split federal ...

Oil and gas production in the United States is hitting record highs, easily outpacing consumption growth and fueling an export boom that in 2020 achieved the country's first trade surplus in energy ...

Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Republicans weigh path forward for ...

As the 119th Congress convenes, policymakers have a historic opportunity to lower prescription drug prices for Americans. As ...

The report shows that PBMs made over $7.3 billion in extra profits from dispensing specialty generic drugs during the study ...

Carl Schmid, executive director of the HIV+Hepatitis Policy Institute in Washington, D.C., talks about the problems associated with generic HIV PrEP drug markups and potential ways to fix it.

Mintz’s Health Law and Antitrust teams actively monitor federal and state regulatory and legislative developments in the PBM ...

Oklahoma's attorney general has accused CVS's Caremark pharmacy benefit manager unit of under-reimbursing pharmacies for ...

An arbitrator has determined Prime Therapeutics violated federal and state antitrust laws against the AIDS Healthcare ...

At a public meeting held on January 15, 2025, the Federal Trade Commission (FTC) summarized the Second Interim Staff Report ...